Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Londo who wrote (1098)	3/19/2001 3:20:38 PM
From: Bosco	Read Replies (1) \| Respond to of 1298

Hi Londo - I tend to be a bit more conservative by not counting the ABGX holding, since it can swing wildly. I believe gene therapy is here to stay. However, the question is CEGE's version. Considering its fairly successful Phase I [ok, so we don't have a reasonable sample size from which to draw conclusion, but then, it is only Phase I] What is left out from Zantac is CEGE's patent portfolio. TXKX/AMGN battle may be a minor setback. Again, conservative investors probably never include that in their estimation. However, that shows CEGE's patent potency. best, Bosco